Data base for:

  • Conferences
  • Research funding opportunities
  • Competitions / Awards

Register for free and add any data by yourself!

Filter conferences

 
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
 
      
      
 
      
European NeoAg Summit 2019

European NeoAg Summit 2019

Categories

Date of beginning

Tuesday, 23 April 2019

Duration

3 days

City

Amsterdam

Country

Netherlands

Contact

Aarti Diwan

E-Mail

This email address is being protected from spambots. You need JavaScript enabled to view it.

Memo

The 3rd Annual European NeoAg Summit is the leading industry-dedicated meeting focused on advancing personalised cancer immunotherapy through neoantigen targeting. Over the last year, there has been a record number of neoantigen-based therapies heading into and through the clinic. In addition, exciting collaborations that bring significant investment into the space means that tumour-specific antigen targeting is set to explode. At the European NeoAg Summit, we bring together the leading pharma and biotech companies to discuss: -Reducing the discordance between various neoantigen prediction methods-Maximising the immune response to neoantigens-Shortening the needle-to-needle time of personalised cancer immunotherapy-Navigating the evolving regulatory landscape to faster approval Join the leaders from BioNTech, Genentech, Genocea, Gritstone Oncology, Agenus, Ziopharm, Vaccibody, the European Medicines Agency and many more to spur on more efficacious personalised cancer vaccines and cell therapies. Prices:Conference + 2 Workshops: EUR 3397.0,Conference + 1 Workshop: EUR 2898.0,Conference only: EUR 2399.0,Workshop Only (Each): EUR 599.0 Speakers: John Castle, Associate Vice President, Head of Translational Medicine and Bioinformatics, Agenus, Andrew Ishizuka, Chief Scientific Officer, Avidea Technologies, Mathias Vormehr, Head of Cancer Vaccines, BioNTech, Michal Bassani-Sternberg, Sternberg Director, Immunopeptidomics Unit Center of Experimental Therapeutics, CHUV, Asterios Tsiftsoglou, Committee for Advanced Therapies Member, European Medicines Agency, LĂ©lia Delamarre, Senior Scientist, Cancer Immunology Research, Genentech, Jessica Flechtner, Chief Scientific Officer, Genocea, Jennifer Busby, Senior Director of Mass Spectrometry and Proteomics, Gritstone Oncology, Norbert Hilf, Director of Translational Development, Immatics, John Wang, Chief Executive Officer, IOVaxis, Trevor Clancy, Chief Scientific Officer, OncoImmunity, Sean Boyle, Director, Bioinformatics Applications, Personalis, Agnete Fredriksen, Chief Scientific Officer, Vaccibody, Laurence Cooper, Chief Executive Officer, Ziopharm, Hans Keirstead, Chief Executive Officer, AIVITA Biomedical, Michael Stein, Executive Chairman, Valo Therapeutics, Anna Pasetto, Assistant Professor, Karolinska Institutet Time: 8:00 am - 5:00 pmVenue details: Amsterdam Marriott Hotel, 12 Stadhouderskade, Amsterdam, 1054 ES, Netherlands